Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Nevro Corp. Common Stock
(NY:
NVRO
)
5.840
UNCHANGED
Last Price
Updated: 7:00 PM EDT, Apr 2, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nevro Corp. Common Stock
< Previous
1
2
3
4
5
Next >
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
↗
February 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...
Via
Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
↗
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
Where Nevro Stands With Analysts
↗
January 12, 2022
Nevro (NYSE:NVRO) has observed the following analyst ratings within the last ...
Via
Benzinga
4 Stocks Insiders Are Buying
↗
November 23, 2021
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t...
Via
Benzinga
Earnings Scheduled For February 23, 2022
↗
February 23, 2022
Companies Reporting Before The Bell • Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter. • Plymouth Industrial REIT (NYSE:PLYM)...
Via
Benzinga
Nevro: Q3 Earnings Insights
↗
November 08, 2021
Nevro (NYSE:NVRO) reported its Q3 earnings results on Monday, November 8, 2021 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Nevro reported...
Via
Benzinga
Preview: Nevro's Earnings
↗
November 05, 2021
Nevro (NYSE:NVRO) is set to give its latest quarterly earnings report on Monday, 2021-11-08. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
↗
January 25, 2022
On Tuesday, 88 companies set new 52-week lows. Interesting Highlights From Today's 52-Week Lows: Credit Suisse Group (NYSE:CS) was the largest, in terms of market cap...
Via
Benzinga
The Daily Biotech Pulse: Gamida Gains On Positive Regulatory Development, Orphazyme & ADMA Preannouncements, ImmunityBio & Leap Present Positive Data
↗
January 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Orphazyme Preannounces Positive FY21 Results Orphazyme A/S (NASDAQ: ORPH)...
Via
Benzinga
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
↗
August 17, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16) Bio-Rad Laboratories, Inc...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022
↗
January 07, 2022
Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE:
Via
Benzinga
What 12 Analyst Ratings Have To Say About Nevro
↗
August 05, 2021
Nevro (NYSE:NVRO) has observed the following analyst ratings within the last...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2021
↗
December 06, 2021
Upgrades According to TD Securities, the prior rating for MAG Silver Corp (AMEX:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 9, 2021
↗
November 09, 2021
Upgrades JP Morgan upgraded the previous rating for New Relic Inc (NYSE:
Via
Benzinga
10 Biggest Price Target Changes For Tuesday
↗
November 09, 2021
Craig-Hallum cut Zix Corporation (NASDAQ:ZIXI) p...
Via
Benzinga
Nevro Corp (NVRO) Q3 2021 Earnings Call Transcript
↗
November 09, 2021
NVRO earnings call for the period ending September 30, 2021.
Via
The Motley Fool
Topics
Earnings
Looking into Nevro's Return on Capital Employed
↗
August 20, 2021
After pulling data from Benzinga Pro it seems like during Q2, Nevro's (NYSE:NVRO) reported sales totaled $102.33 million. Despite a 29.98% in earnings, the company posted a loss...
Via
Benzinga
Why Nevro Is Falling So Hard Today
↗
August 05, 2021
A narrower-than-expected loss was about the only bright spot in the company's second-quarter results.
Via
The Motley Fool
Mid-Afternoon Market Update: Nasdaq Rises 100 Points; SiTime Shares Gain After Strong Q2 Results
↗
August 05, 2021
Toward the end of trading Thursday, the Dow traded up 0.58% to 34,994.11 while the NASDAQ rose 0.69% to 14,881.97. The S&P also rose, gaining 0.42% to 4,421.35. The U.S. has...
Via
Benzinga
Topics
Stocks
The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More
↗
November 08, 2021
Biotech stocks reversed course and closed the week ended Nov. 5 lower, squandering the gains notched early in the week. What was good news for Pfizer, Inc. (NYSE: PFE) turned out...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
August 05, 2021
Gainers Nautilus Biotechnology (NASDAQ:NAUT) stock rose 25.23% to $9.38 during Thursday's regular session. Nautilus Biotechnology's stock is trading at a volume of...
Via
Benzinga
Earnings Scheduled For November 8, 2021
↗
November 08, 2021
Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $0.11 per share on revenue of $215.14 million. •...
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
↗
August 16, 2021
On Monday morning, 207 companies hit new 52-week lows. Intriguing Points: The largest company in terms of market cap to set a new 52-week low was Koninklijke Philips (NYSE...
Via
Benzinga
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
↗
August 12, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) Adagio Therapeutics, Inc. (...
Via
Benzinga
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
↗
August 06, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)...
Via
Benzinga
99 Biggest Movers From Yesterday
↗
August 06, 2021
Gainers Score Media and Gaming Inc. (NASDAQ: SCR) shares climbed 79.9% to close at $32.64 on Thursday after the company, and Penn National Gaming, announced they entered into a...
Via
Benzinga
Mid-Day Market Update: Dow Surges 200 Points; Itron Shares Tumble Following Downbeat Earnings
↗
August 05, 2021
Midway through trading Thursday, the Dow traded up 0.58% to 34,992.85 while the NASDAQ rose 0.61% to 14,870.44. The S&P also rose, gaining 0.14% to 4,420.81. The U.S. has the...
Via
Benzinga
Topics
Stocks
Nevro Stock Tanks After Q2 Earnings Miss, Analysts Move To Sidelines
↗
August 05, 2021
Nevro Corp (NYSE: NVRO) posted second-quarter revenue of $102.3 million, +81% Y/Y, missing the consensus of $107.7 million. Total U.S. permanent implant procedures...
Via
Benzinga
Topics
Earnings
Mid-Morning Market Update: Markets Open Higher; Kellogg Tops Q2 Views
↗
August 05, 2021
Following the market opening Thursday, the Dow traded up 0.49% to 34,961.76 while the NASDAQ rose 0.39% to 14,837.81. The S&P also rose, gaining 0.34% to 4,417.73. The U.S....
Via
Benzinga
Topics
Stocks
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2021
↗
August 05, 2021
Upgrades Stephens & Co. upgraded the previous rating for Roku Inc (NASDAQ:
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.